• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

水基型环吡酮胺搽剂与标准阿莫罗芬搽剂对健康受试者的指甲穿透力和预测真菌疗效的比较。

Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects.

机构信息

Department of Pharmaceutical Sciences, University of Pisa, Pisa, Italy.

出版信息

J Eur Acad Dermatol Venereol. 2013 Feb;27(2):e153-8. doi: 10.1111/j.1468-3083.2012.04529.x. Epub 2012 Mar 26.

DOI:10.1111/j.1468-3083.2012.04529.x
PMID:22449201
Abstract

BACKGROUND

In a previous study a new hydrosoluble nail lacquer (P-3051) containing 8% ciclopirox (CPX) showed higher nail penetration compared to a water-insoluble 5% amorolfine (MRF) lacquer. To our knowledge, in vivo human data on a similar topic are not available.

OBJECTIVES

To compare fingernail penetration of P-3051 with that of MRF reference in humans and to evaluate their predicted efficacy against Trichophyton rubrum and Candida parapsilosis.

METHODS

Single centre, randomized, multiple dose, open label, within subjects study. Test and reference were self-applied to all fingernails of either hand for 28 days. At baseline and after 15 and 25 days, the nail free edge was collected for analysis. Efficiency coefficients were calculated for T. rubrum and C. parapsilosis as ratios of nail concentration/minimum inhibitory concentration. The coefficients were classified as very high, high or poor.

RESULTS

Nail concentrations after 15 days were 2.82 ± 0.58 μg/mg for CPX and 0.64 ± 0.11 μg/mg for MRF. At day 25 there was a non-significant decline (1.85 ± 0.31 μg/mg, P = 0.077) for CPX and a highly significant (0.13 ± 0.03 μg/mg, P = 0.0002) 80% decline for MRF. Efficiency coefficients were very high/high in all subjects treated with P-3051 against both T. rubrum and C. parapsilosis; they were significantly lower for MRF reference against both pathogens at both observation points.

CONCLUSIONS

P-3051 exhibited better penetration and higher predicted efficacy after in vivo multiple application to human fingernails when compared to MRF reference. These in vivo data are in good agreement with our previous in vitro study.

摘要

背景

在之前的一项研究中,一种新的水溶性指甲漆(P-3051),含有 8%环吡酮(CPX),与不溶于水的 5%阿莫罗芬(MRF)漆相比,显示出更高的指甲穿透力。据我们所知,目前尚无类似主题的人体体内数据。

目的

比较 P-3051 与 MRF 参考制剂在人体指甲中的穿透情况,并评估它们对红色毛癣菌和近平滑念珠菌的预测疗效。

方法

单中心、随机、多剂量、开放性、自身对照研究。试验和参考制剂在 28 天内每天自行涂抹于双手的所有指甲。在基线以及第 15 天和第 25 天,采集指甲游离缘进行分析。针对红色毛癣菌和近平滑念珠菌,计算效率系数作为指甲浓度/最低抑菌浓度的比值。根据比值将系数分为很高、高或差。

结果

第 15 天时 CPX 的指甲浓度为 2.82±0.58μg/mg,MRF 为 0.64±0.11μg/mg。第 25 天时 CPX 呈非显著性下降(1.85±0.31μg/mg,P=0.077),而 MRF 则呈高度显著性下降(0.13±0.03μg/mg,P=0.0002),下降 80%。所有接受 P-3051 治疗的患者,其指甲对红色毛癣菌和近平滑念珠菌的效率系数均很高或很高;而 MRF 参考制剂在两个观察点的所有患者中对这两种病原体的效率系数均显著较低。

结论

与 MRF 参考制剂相比,P-3051 在多次应用于人体指甲后的体内穿透性和预测疗效更好。这些体内数据与我们之前的体外研究结果一致。

相似文献

1
Nail penetration and predicted mycological efficacy of an innovative hydrosoluble ciclopirox nail lacquer vs. a standard amorolfine lacquer in healthy subjects.水基型环吡酮胺搽剂与标准阿莫罗芬搽剂对健康受试者的指甲穿透力和预测真菌疗效的比较。
J Eur Acad Dermatol Venereol. 2013 Feb;27(2):e153-8. doi: 10.1111/j.1468-3083.2012.04529.x. Epub 2012 Mar 26.
2
Hydrosoluble medicated nail lacquers: in vitro drug permeation and corresponding antimycotic activity.水溶药物指甲漆:体外药物渗透及其相应的抗真菌活性。
Br J Dermatol. 2010 Feb 1;162(2):311-7. doi: 10.1111/j.1365-2133.2009.09504.x. Epub 2009 Nov 3.
3
Antifungal activity, experimental infections and nail permeation of an innovative ciclopirox nail lacquer based on a water-soluble biopolymer.基于水溶性生物聚合物的创新型环吡酮指甲漆的抗真菌活性、实验性感染及指甲渗透性
J Drugs Dermatol. 2010 May;9(5):525-30.
4
A randomized comparison of nail surface remanence of three nail lacquers, containing amorolfine 5%, ciclopirox 8% or tioconazole 28%, in healthy volunteers.在健康志愿者中对三种指甲油(分别含有5%阿莫罗芬、8%环吡酮或28%噻康唑)的指甲表面残留量进行的随机比较。
Int J Tissue React. 2004;26(1-2):17-24.
5
Ciclopirox vs amorolfine: in vitro penetration into and permeation through human healthy nails of commercial nail lacquers.环吡酮与阿莫罗芬:市售指甲油对人健康指甲的体外渗透及透过情况
J Drugs Dermatol. 2014 Feb;13(2):143-7.
6
A multicenter, randomized, open-label, controlled study comparing the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution with amorolfine nail lacquer alone in dermatophytic onychomycosis.一项多中心、随机、开放标签、对照研究,比较RV4104A软膏、环吡酮胺乳膏和环吡酮成膜溶液序贯疗法与阿莫罗芬搽剂单独使用治疗皮肤癣菌性甲真菌病的疗效、安全性和成本效益。
Dermatology. 2013;227(2):157-64. doi: 10.1159/000353667.
7
A pilot, layerwise, ex vivo evaluation of the antifungal efficacy of amorolfine 5% nail lacquer vs other topical antifungal nail formulations in healthy toenails.一项在健康趾甲中评估阿莫罗芬 5%指甲油与其他局部抗真菌趾甲制剂抗真菌疗效的分层、离体初步研究。
Mycoses. 2019 Jun;62(6):494-501. doi: 10.1111/myc.12896. Epub 2019 Mar 18.
8
Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis.8%环吡酮甲涂剂局部溶液治疗趾甲甲真菌病
J Am Acad Dermatol. 2000 Oct;43(4 Suppl):S70-80. doi: 10.1067/mjd.2000.109071.
9
A multicenter, open-label study of the efficacy and safety of ciclopirox nail lacquer solution 8% for the treatment of onychomycosis in patients with diabetes.一项关于8%环吡酮甲涂剂溶液治疗糖尿病患者甲癣疗效和安全性的多中心、开放标签研究。
Cutis. 2001 Aug;68(2 Suppl):17-22.
10
The dermatopharmacologic profile of ciclopirox 8% nail lacquer.8%环吡酮甲涂剂的皮肤药理学特征
J Am Podiatr Med Assoc. 2000 Nov-Dec;90(10):491-4. doi: 10.7547/87507315-90-10-491.

引用本文的文献

1
Lipid-based nanoformulations in onychomycosis therapy: addressing challenges of current therapies and advancing treatment.基于脂质的纳米制剂在甲癣治疗中的应用:应对当前治疗的挑战并推进治疗进展
RSC Adv. 2025 Mar 11;15(10):7799-7825. doi: 10.1039/d5ra00387c. eCollection 2025 Mar 6.
2
Formulation and Antimycotic Evaluation of Colloidal Itraconazole-Loaded Metered Dose Sprays for Treating Superficial Mycoses.胶体酮康唑载计量喷雾制剂的配方与抗真菌评价用于治疗浅部真菌病。
AAPS PharmSciTech. 2024 Jul 9;25(6):156. doi: 10.1208/s12249-024-02879-7.
3
Nail Society of India (NSI) Recommendations for Pharmacologic Therapy of Onychomycosis.
印度指甲协会(NSI)关于甲癣药物治疗的建议。
Indian Dermatol Online J. 2023 Apr 27;14(3):330-341. doi: 10.4103/idoj.idoj_355_22. eCollection 2023 May-Jun.
4
Updated Perspectives on the Diagnosis and Management of Onychomycosis.甲癣诊断与治疗的最新观点
Clin Cosmet Investig Dermatol. 2022 Sep 15;15:1933-1957. doi: 10.2147/CCID.S362635. eCollection 2022.
5
Ciclopirox Hydroxypropyl Chitosan (CPX-HPCH) Nail Lacquer and Breathable Cosmetic Nail Polish: In Vitro Evaluation of Drug Transungual Permeation Following the Combined Application.环吡酮羟丙基壳聚糖(CPX-HPCH)指甲油和透气型美容指甲油:联合应用后药物经指甲渗透的体外评价
Life (Basel). 2022 May 27;12(6):801. doi: 10.3390/life12060801.
6
Ciclopirox Hydroxypropyl Chitosan (HPCH) Nail Lacquer: A Review of Its Use in Onychomycosis.环吡酮羟丙基壳聚糖(HPCH)指甲油:其在甲真菌病治疗中的应用综述
Dermatol Ther (Heidelb). 2020 Oct;10(5):917-929. doi: 10.1007/s13555-020-00420-9. Epub 2020 Jul 23.
7
Ciclopirox and Efinaconazole Transungual Permeation, Antifungal Activity, and Proficiency To Induce Resistance in Trichophyton rubrum.环吡酮胺和依氟康唑经皮渗透、抗真菌活性及诱导红色毛癣菌耐药的能力。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00442-19. Print 2019 Oct.
8
Polyurethanes as New Excipients in Nail Therapeutics.聚氨酯作为指甲治疗中的新型辅料
Pharmaceutics. 2018 Dec 13;10(4):276. doi: 10.3390/pharmaceutics10040276.
9
Human Onychopharmacokinetic and Pharmacodynamic Analyses of ME1111, a New Topical Agent for Onychomycosis.人指甲药代动力学和药效学分析 ME1111,一种治疗甲真菌病的新型局部药物。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.00779-17. Print 2018 Jan.
10
Repositioning the Old Fungicide Ciclopirox for New Medical Uses.重新定位旧的杀真菌剂环吡酮用于新的医学用途。
Curr Pharm Des. 2016;22(28):4443-50. doi: 10.2174/1381612822666160530151209.